课题基金 / 基金详情

Metabolic consequences of securin disruption

Metabolic consequences of securin disruption
securin 破坏的代谢后果
批准号:
7008190
负责人:
SHLOMO MELMED
金额:
$31.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-03-01 至 2008-01-31

项目摘要

项目成果

SHLOMO MELMED的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cell cycle-dependent securin proteins regulate sister chromatid separation by inhibiting separin function. We isolated and have characterized pituitary tumor transforming gene (PTTG) from rat pituitary tumor cells, and PTTG is functionally homologous to yeast securin. PTTG is overexpressed in several tumor types, and also in some normal replicating tissues (including testis, lympocytes). When the PTTG gene was deleted, resultant knockout mice were viable, fertile and exhibited splenic and testicular hypoplasia and thrombocytopenia. Surprisingly, after 6 months, male PTTG -/- mice do not gain weight, develop profound hyperglycemia, hypo-insulinemia, and hypo-leptinemia with intact insulin sensitivity. In preliminary experiments, pancreatic beta cells appear hypoplastic with diminished islet insulin immunoreactivity, and no evidence for autoimmune islet involvement. This proposal aims to study the role of mammalian securin in pancreatic beta cell function by assessing insulin transcription, secretion and action, regulation of adipocyte hormones and assessment of pancreatic beta cell development and replication, and pancreatic regeneration. As securin-deficient diabetes is restricted to male mice, intact or gonadectomized PTTG -/- animals will be treated with sex steroids, and their impact on glycemia and pancreatic function assessed. These studies highlight the role of a cell cycle-regulating protein in pancreatic beta cell development and function. In the context of this unique genetic background, these experiments identify securin as a critical factor for pancreatic cell function and provide insights into a novel monogenic cause of diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)
  • 批准号:
    10003845
  • 项目类别:
  • 资助金额:
    $46.78万
  • 财政年份:
    2018
  • 负责人:
    SHLOMO MELMED
  • 依托单位:
Mechanisms for GH action on epithelial cells
  • 批准号:
    10578571
  • 项目类别:
  • 资助金额:
    $36.74万
  • 财政年份:
    2018
  • 负责人:
    SHLOMO MELMED
  • 依托单位:
Mechanisms for GH action on epithelial cells
  • 批准号:
    9893867
  • 项目类别:
  • 资助金额:
    $38.25万
  • 财政年份:
    2018
  • 负责人:
    SHLOMO MELMED
  • 依托单位:
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovit
  • 批准号:
    8773516
  • 项目类别:
  • 资助金额:
    $23.44万
  • 财政年份:
    2014
  • 负责人:
    SHLOMO MELMED
  • 依托单位:
国内基金
海外基金
Accretion variability and its consequences: from protostars to planet-forming disks
  • 批准号:
    12173003
  • 项目类别:
    面上项目
  • 资助金额:
    60万元
  • 批准年份:
    2021
  • 负责人:
    沈雷歌
  • 依托单位:
Exposing Verifiable Consequences of the Emergence of Mass
  • 批准号:
    12135007
  • 项目类别:
    重点项目
  • 资助金额:
    313万元
  • 批准年份:
    2021
  • 负责人:
    Craig Darrian Roberts
  • 依托单位:
Consequences of MALT1 mutation for B cell tolerance
  • 批准号:
    32100719
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    James Qun Wang
  • 依托单位: